The Long Game

In this episode, Sandy and Ross delve into the world of peptides, discussing their uses, risks, and the burgeoning market surrounding them. They explore specific peptides like BPC 157 and Melanotan, highlighting the lack of regulation and scientific backing for many products available online. The conversation delves into the complexities of peptide medicines, their market dynamics, regulatory challenges, and the future of peptide research. It also touches on personal anecdotes and the importance of evidence in the context of wellness optimization.

Key Takeaways

• Peptides are gaining popularity
• Regulation and safety are concerns Peptide medicines require rigorous testing
• Consumer demand drives peptide market

The NHS has some of the most valuable health data in the world and that makes it both a goldmine and a battleground.

In the latest episode of The Long Game, Sandy Weir and Ross Cagan pull apart the promise, the politics, and the very real risks of letting Silicon Valley companies help run the systems behind your care. They start with the Royal Free and DeepMind case, where 1.6 million patient records were shared without patients being individually asked for consent, then move to the bigger question now facing the NHS: what happens when companies like Palantir sit at the centre of the data infrastructure that powers care, research, and AI?

You'll discover why NHS data is so attractive to technology companies, what “data processor” vs “data controller” actually means in practice, and why trust can collapse even when the legal basis looks sound.

Sandy and Ross break down the hidden danger of vendor lock-in, the importance of interoperability and exit planning, and why standardised platforms may matter as much as the software itself.

We also get into the upside that keeps this conversation from becoming anti-tech. Ambient AI is already cutting documentation time dramatically, some pilots are reportedly slashing admin workloads by 80%, and linked data can improve diagnosis, scheduling, discharge, and research at scale. But those gains only matter if the public can see what they are getting back. The episode also revisits care.data, the NHS rollout that spent over a million pounds mailing leaflets to 22 million households only to collapse under public backlash, and the WannaCry attack, which showed how fragile healthcare infrastructure becomes when systems are outdated and security is weak.

The message is clear; in health data, trust is infrastructure. Essential listening if you care about AI in healthcare, public data, NHS reform, or the future of who gets to profit from the information we all help create.

The final question is the one that matters most, what should the public get back when its data creates private value?

The future of newborn screening sounds simple until you ask the hard question: should every baby have their whole genome sequenced at birth?

Sandy Weir and Ross Cagan unpack the promise, the technology, and the uncomfortable trade-offs behind one of the biggest shifts in modern healthcare. With the NHS Generation Study already sequencing newborns across England, this episode explores how ultra-fast genome reading could catch rare, treatable diseases before symptoms appear, potentially sparing families years of uncertainty, misdiagnosis, and delayed care. But as Sandy and Ross make clear, reading DNA is only the beginning.

They break down:

• why whole genome sequencing could transform rare disease diagnosis
• what the Generation Study is actually screening for, including 223 rare conditions across more than 500 genes
• why variants of unknown significance can create anxiety instead of answers
• how penetrance, adult-onset risk, and future autonomy complicate consent
• why storing a baby's genome raises questions about access, reanalysis, and lifetime data control

Ross also explains why the real bottleneck is not sequencing speed, but interpretation, counselling, follow-up, and the full care pathway that turns data into something useful.

Sandy pushes on the fairness question too: if genomic foresight becomes a public good, who gets access, who pays, and what happens if it becomes another divide between wealthy families and everyone else?

If you care about genetics, public health, medical ethics, or the future of personalised medicine, this conversation is essential listening. It is a sharp, accessible look at how close we are to sequencing every baby, and why the real debate is not whether we can do it, but whether we should.

Women’s health is not a niche market, it’s a massive blind spot in medicine, investment, and product design.

Ross Cagan and Sandy Weir unpack how decades of male-default research created real-world harm, from delayed diagnoses to missed heart attacks, and why that neglect is now becoming one of the biggest opportunities in health. They break down the data problem at the centre of the women’s health gap, including why female biology was historically excluded from studies, why that assumption turned out to be wrong, and how missing data leads to missing diagnoses. You’ll hear why endometriosis can take 8 to 10 years to diagnose, how menopause affects careers and productivity, and why cardiovascular disease is still misread in women more often than it should be.

Ross and Sandy also explore the rise of FemTech, from period tracking and fertility apps to pelvic health, contraception, and non-invasive diagnostics, and why the category needed a name before investors would take it seriously. They dig into the privacy and governance risks around sensitive reproductive data, especially after Roe v. Wade was overturned, and ask what happens when wellness tools sit somewhere between consumer app and medical advice.

You’ll also discover:

• Why a meta-analysis of 293 studies challenged the old excuse for excluding female mice from research
• How non-invasive testing could shorten the road to endometriosis diagnosis
• Why menopause is both a health issue and a workforce issue
• What the women’s health market could mean economically if the gap is finally closed

This conversation makes one thing clear: women’s health is a stress test for whether medicine can correct its own blind spots. It’s essential listening if you care about better care, better data, and a health system that serves half the population as more than an afterthought.

Private full-body MRIs are booming - but are you buying peace of mind or simply new things to worry about? Healthy people are lining up for scans that promise certainty, early detection, and control. Sandy Weir and Ross Cagan reveal why that promise can backfire, turning reassurance into anxiety, follow-up tests, and overdiagnosis. This episode unpacks the private scan boom and the uncomfortable truth behind elective whole-body MRI. Ross and Sandy explain why scanning a healthy body is not the same as investigating symptoms, and why the difference matters more than most marketing ever admits. When a scan finds a tiny cyst, nodule, or shadow, the question is not just "what is it?", it is "can you unsee it?"

Most longevity clinics are selling a seductive story, not proven results. If you care about biological age tests, rapamycin, supplements, or the booming market for “optimization,” this episode separates the real science from the expensive theatre. Ross Cagan and Sandy Weir take on the new body economy and ask the question at the centre of the longevity clinic boom: what actually improves health span, and what is just measurement, hope, and status wrapped in a premium price tag? The answer is more nuanced than the hype suggests, and far less magical than the marketing.

The Ozempic economy is already reshaping what people eat, how companies sell, and which health systems can afford to keep up. Sandy Weir and Ross Kagan kick off The Body Economy, a six-part series that starts with the drugs behind the headlines and ends with a much bigger question: what happens when appetite itself becomes medically adjustable?

One contaminated lab plate helped launch a multi-billion-dollar industry, save hundreds of millions of lives, and trigger one of the biggest IP blunders in British history. Ross Cagan and Sandy Weir trace the penicillin story from Alexander Fleming's messy "failed" experiment to the commercialisation race that changed medicine forever. They unpack how Fleming spotted the blue-green mould that killed staph bacteria, why his breakthrough sat ignored for a decade, and how Howard Florey and Ernest Chain turned the discovery into a scalable manufacturing process during World War Two. Along the way, they reveal why the real breakthrough wasn't just scientific, it was industrial, legal, and deeply political.

A doctor tried to erase two murders so completely that he turned the crime scene into a puzzle.

What finally exposed the truth was not a confession, but forensic ingenuity; skull reconstruction, photographic superimposition, and insects that could timestamp death with uncanny precision.

Ross Cagan and Sandy Weir unpack the infamous Buck Ruxton case, known as the Jigsaw Murders and Bodies Under the Bridge, and show how a 1935 killing in Moffat helped redefine modern forensic science.

The placebo effect is far more powerful, and potentially more dangerous, than most people realise. Expectation can trigger real biochemical changes in the brain, ease symptoms, and even nudge dopamine release in Parkinson's disease, but it can also create side effects out of thin air and quietly distort treatment decisions.

In the second part of their examination of the placebo effect, Sandy Weir and Ross Cagan dig further into the science behind placebo and nocebo, showing why "feeling better" is not the same as "being better." They use striking examples from Parkinson's, asthma, COVID vaccine trials, pain relief, and cancer care to show where placebo responses help, where they mislead, and why the line matters so much in real medicine.